{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:53:38Z","timestamp":1792058018468,"version":"4.4.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.biopha.2007.05.004","type":"journal-article","created":{"date-parts":[[2007,6,14]],"date-time":"2007-06-14T01:04:48Z","timestamp":1181783088000},"page":"299-305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":161,"title":["Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: A success story with room for improvement"],"prefix":"10.1016","volume":"61","author":[{"given":"Sven","family":"Brandau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Suttmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2007.05.004_bib1","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1128\/jb.178.5.1274-1282.1996","article-title":"Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis","volume":"178","author":"Mahairas","year":"1996","journal-title":"J Bacteriol."},{"key":"10.1016\/j.biopha.2007.05.004_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1086\/345862","article-title":"Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette\u2013Gu\u00e9rin attenuation","volume":"187","author":"Lewis","year":"2003","journal-title":"J Infect Dis."},{"key":"10.1016\/j.biopha.2007.05.004_bib3","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/978-1-4684-5766-7_52","article-title":"Coley toxins\u2014the first century","volume":"267","author":"Coley-Nauts","year":"1990","journal-title":"Adv Exp Med Biol."},{"key":"10.1016\/j.biopha.2007.05.004_bib4","first-page":"97","article-title":"Cancer and tuberculosis","volume":"9","author":"Pearl","year":"1929","journal-title":"Am J Hyg."},{"key":"10.1016\/j.biopha.2007.05.004_bib5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(69)92648-8","article-title":"Active immunotherapy for acute lymphoblastic leukaemia","volume":"1","author":"Mathe","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2007.05.004_bib6","first-page":"158","article-title":"Immunological factors which influence response to immunotherapy in malignant melanoma","volume":"68","author":"Morton","year":"1970","journal-title":"Surgery"},{"key":"10.1016\/j.biopha.2007.05.004_bib7","first-page":"831","article-title":"Suppression of tumor growth at the site of infection with living Bacillus Calmette\u2013Gu\u00e9rin","volume":"46","author":"Zbar","year":"1971","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.biopha.2007.05.004_bib8","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/1097-0142(197410)34:8+<1532::AID-CNCR2820340827>3.0.CO;2-H","article-title":"Immunotherapy of guinea pig cancer with BCG","volume":"34","author":"Zbar","year":"1974","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2007.05.004_bib9","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette\u2013Gu\u00e9rin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib10","first-page":"10","volume":"55","author":"Jemal","year":"2005","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.biopha.2007.05.004_bib11","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette\u2013Gu\u00e9rin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib13","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette\u2013Gu\u00e9rin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette\u2013Gu\u00e9rin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib15","first-page":"65","article-title":"A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette\u2013Gu\u00e9rin for superficial bladder cancer","volume":"144","author":"Lamm","year":"1990","journal-title":"J\u00a0Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib16","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0022-5347(17)38439-2","article-title":"Prospective randomized comparison of intravesical with percutaneous bacillus Calmette\u2013Gu\u00e9rin versus intravesical bacillus Calmette\u2013Gu\u00e9rin in superficial bladder cancer","volume":"145","author":"Lamm","year":"1991","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0022-5347(01)66427-9","article-title":"Intravesical versus intravesical plus intradermal bacillus Calmette\u2013Gu\u00e9rin: a prospective randomized study in patients with recurrent superficial bladder tumors","volume":"155","author":"L\u00fcftenegger","year":"1996","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib18","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette\u2013Gu\u00e9rin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.eururo.2004.04.011","article-title":"EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma","volume":"46","author":"Oosterlinck","year":"2004","journal-title":"Eur Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib20","first-page":"596","article-title":"Incidence and treatment of complications of bacillus Calmette\u2013Gu\u00e9rin intravesical therapy in superficial bladder cancer","volume":"147","author":"Lamm","year":"1992","journal-title":"J\u00a0Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance Bacillus Calmette\u2013Gu\u00e9rin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"van der Meijden","year":"2003","journal-title":"Eur Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0090-4295(01)00921-9","article-title":"Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.biopha.2007.05.004_bib23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/1097-0142(19870801)60:3<326::AID-CNCR2820600309>3.0.CO;2-5","article-title":"Toxicity of intravesical BCG and its management in patients with superficial bladder tumors","volume":"60","author":"Orihuela","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2007.05.004_bib24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0302-2838(03)00371-3","article-title":"The side effects of Bacillus Calmette\u2013Gu\u00e9rin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"Sylvester","year":"2003","journal-title":"Eur Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00262-003-0384-9","article-title":"Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette\u2013Gu\u00e9rin immunotherapy for carcinoma in situ of the bladder","volume":"52","author":"Watanabe","year":"2003","journal-title":"Cancer Immunol Immunother."},{"key":"10.1016\/j.biopha.2007.05.004_bib26","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","article-title":"Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette\u2013Gu\u00e9rin","volume":"164","author":"Thalmann","year":"2000","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib27","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/S0022-5347(01)64210-1","article-title":"Interleukin-8 expression in the urine after bacillus Calmette\u2013Gu\u00e9rin therapy: a potential prognostic factor of tumor recurrence and progression","volume":"158","author":"Thalmann","year":"1997","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib28","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.1987.5.3.441","article-title":"A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette\u2013Gu\u00e9rin therapy of superficial bladder cancer","volume":"5","author":"Badalament","year":"1987","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.biopha.2007.05.004_bib29","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z","article-title":"NK cells are essential for effective BCG immunotherapy","volume":"92","author":"Brandau","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.biopha.2007.05.004_bib30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1046\/j.1365-2249.2002.01734.x","article-title":"IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer","volume":"127","author":"Riemensberger","year":"2002","journal-title":"Clin Exp Immunol."},{"key":"10.1016\/j.biopha.2007.05.004_bib31","doi-asserted-by":"crossref","first-page":"8250","DOI":"10.1158\/0008-5472.CAN-06-1416","article-title":"Neutrophil granulocytes are required for effective Bacillus Calmette\u2013Gu\u00e9rin immunotherapy of bladder cancer and orchestrate local immune responses","volume":"66","author":"Suttmann","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2007.05.004_bib32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0022-5347(17)43909-7","article-title":"Requirement of a thymus-dependant immune response for BCG-mediated antitumor activity","volume":"137","author":"Ratliff","year":"1987","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib33","first-page":"1018","article-title":"T-cell subsets required for intravesical BCG immunotherapy for bladder cancer","volume":"150","author":"Ratliff","year":"1993","journal-title":"J\u00a0Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI114434","article-title":"Fibronectin-mediated Calmette\u2013Gu\u00e9rin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response","volume":"85","author":"Kavoussi","year":"1990","journal-title":"J Clin Invest."},{"key":"10.1016\/j.biopha.2007.05.004_bib35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<83::AID-IJC13>3.0.CO;2-R","article-title":"Role of a bacillus Calmette\u2013Gu\u00e9rin fibronectin attachment protein in BCG-induced antitumor activity","volume":"86","author":"Zhao","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.biopha.2007.05.004_bib36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00296835","article-title":"Cytokine production by the human bladder carcinoma cell line T24 in the presence of Bacillus Calmette\u2013Gu\u00e9rin","volume":"21","author":"de Reijke","year":"1993","journal-title":"Urol Res."},{"key":"10.1016\/j.biopha.2007.05.004_bib37","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0022-5347(01)67113-1","article-title":"Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy","volume":"154","author":"Esuvaranathan","year":"1995","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00294021","article-title":"Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis","volume":"19","author":"de Boer","year":"1991","journal-title":"Urol Res."},{"key":"10.1016\/j.biopha.2007.05.004_bib39","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-04-0374","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette\u2013Gu\u00e9rin-induced antitumor activity","volume":"64","author":"Ludwig","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2007.05.004_bib40","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1128\/IAI.71.8.4647-4656.2003","article-title":"Stimulation of neutrophil granulocytes with Mycobacterium bovis bacillus Calmette\u2013Gu\u00e9rin induces changes in phenotype and gene expression and inhibits spontaneous apoptosis","volume":"71","author":"Suttmann","year":"2003","journal-title":"Infect Immun."},{"key":"10.1016\/j.biopha.2007.05.004_bib41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-5347(17)39365-5","article-title":"Effects of local bacillus Calmette\u2013Gu\u00e9rin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall","volume":"144","author":"B\u00f6hle","year":"1990","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib42","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/S0022-5347(17)37668-1","article-title":"Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall","volume":"147","author":"Prescott","year":"1992","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-5347(17)39366-7","article-title":"Elevations of cytokines interleukin-1, interleukin-2, and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette\u2013Gu\u00e9rin immunotherapy","volume":"144","author":"B\u00f6hle","year":"1990","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib44","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0022-5347(17)45142-1","article-title":"Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG","volume":"136","author":"Haaff","year":"1986","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib45","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0022-5347(17)39713-6","article-title":"Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy","volume":"144","author":"Prescott","year":"1990","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib46","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1365-2249.2006.03288.x","article-title":"Mycobacterium bovis bacillus Calmette\u2013Gu\u00e9rin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo","volume":"147","author":"Luo","year":"2007","journal-title":"Clin Exp Immunol."},{"key":"10.1016\/j.biopha.2007.05.004_bib47","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.4049\/jimmunol.163.8.4246","article-title":"Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette\u2013Gu\u00e9rin","volume":"163","author":"O'Donnell","year":"1999","journal-title":"J Immunol."},{"key":"10.1016\/j.biopha.2007.05.004_bib48","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/01.ju.0000131944.52354.63","article-title":"Mechanisms of bacillus Calmette\u2013Gu\u00e9rin-mediated natural killer cell activation","volume":"172","author":"Suttmann","year":"2004","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib49","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0022-5347(17)37582-1","article-title":"The inhibitory effects of interferon gamma on the growth of bladder cancer cells","volume":"147","author":"Hawkyard","year":"1992","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib50","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4049\/jimmunol.162.4.2399","article-title":"IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette\u2013Gu\u00e9rin immunotherapy","volume":"162","author":"Luo","year":"1999","journal-title":"J Immunol."},{"key":"10.1016\/j.biopha.2007.05.004_bib51","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF01520291","article-title":"The induction of bacillus-Calmette\u2013Gu\u00e9rin-activated killer cells requires the presence of monocytes and T-helper type-1 cells","volume":"40","author":"Thanh\u00e4user","year":"1995","journal-title":"Cancer Immunol Immunother."},{"key":"10.1016\/j.biopha.2007.05.004_bib52","first-page":"3729","article-title":"Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette\u2013Gu\u00e9rin-activated killer cells","volume":"6","author":"Brandau","year":"2000","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.biopha.2007.05.004_bib53","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1159\/000052497","article-title":"Activation of natural killer cells by Bacillus Calmette\u2013Gu\u00e9rin","volume":"39","author":"Brandau","year":"2001","journal-title":"Eur Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib54","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000085934","article-title":"Fas ligand and TNF-related apoptosis-inducing ligand induction on infiltrating lymphocytes in bladder carcinoma by bacillus Calmette\u2013Gu\u00e9rin treatment","volume":"75","author":"Mehmut","year":"2005","journal-title":"Urol Int."},{"key":"10.1016\/j.biopha.2007.05.004_bib55","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semcancer.2005.11.005","article-title":"Regulatory T cells in immune surveillance and treatment of cancer","volume":"16","author":"Yamaguchi","year":"2006","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.biopha.2007.05.004_bib56","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.juro.2006.08.078","article-title":"Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines","volume":"177","author":"Loskog","year":"2007","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib57","first-page":"12","article-title":"Local and systemic immune suppression in bladder cancer","volume":"177","author":"Brandau","year":"2007","journal-title":"J\u00a0Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib58","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","article-title":"Innate immune recognition","volume":"20","author":"Janeway","year":"2002","journal-title":"Annu Rev Immunol."},{"key":"10.1016\/j.biopha.2007.05.004_bib59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1472-9792(02)00089-6","article-title":"Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis","volume":"83","author":"Brennan","year":"2003","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.biopha.2007.05.004_bib60","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1084\/jem.20021468","article-title":"DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells","volume":"197","author":"Tailleux","year":"2003","journal-title":"J Exp Med."},{"key":"10.1016\/j.biopha.2007.05.004_bib61","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1128\/IAI.68.12.6883-6890.2000","article-title":"Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette\u2013Gu\u00e9rin: involvement of toll-like receptors","volume":"68","author":"Tsuji","year":"2000","journal-title":"Infect Immun."},{"key":"10.1016\/j.biopha.2007.05.004_bib62","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.4049\/jimmunol.176.9.5173","article-title":"Mycobacteria induce IFN-{gamma} production in human dendritic cells via triggering of TLR2","volume":"176","author":"Fricke","year":"2006","journal-title":"J Immunol."},{"key":"10.1016\/j.biopha.2007.05.004_bib63","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nrc1782","article-title":"Paradoxical roles of the immune system during cancer development","volume":"6","author":"de Visser","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.biopha.2007.05.004_bib64","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1158\/1078-0432.CCR-06-0944","article-title":"Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms","volume":"12","author":"Lizee","year":"2006","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.biopha.2007.05.004_bib65","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2006.01.017","article-title":"Management of BCG failures in superficial bladder cancer: a review","volume":"49","author":"Witjes","year":"2006","journal-title":"Eur Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib66","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00002371-200307000-00006","article-title":"Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder","volume":"26","author":"Weiss","year":"2003","journal-title":"J Immunother."},{"key":"10.1016\/j.biopha.2007.05.004_bib67","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.ju.0000136446.37840.0a","article-title":"Interim results from a national multicenter phase II trial of combination bacillus Calmette\u2013Gu\u00e9rin plus interferon alfa-2b for superficial bladder cancer","volume":"172","author":"O'Donnell","year":"2004","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib68","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00002371-200403000-00005","article-title":"Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma","volume":"27","author":"Arnold","year":"2004","journal-title":"J Immunother."},{"key":"10.1016\/j.biopha.2007.05.004_bib69","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette\u2013Gu\u00e9rin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial","volume":"174","author":"Martinez-Pineiro","year":"2005","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib70","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette\u2013Gu\u00e9rin with a reduced dose of 27 mg in superficial bladder cancer","volume":"89","author":"Martinez-Pineiro","year":"2002","journal-title":"BJU Int."},{"key":"10.1016\/j.biopha.2007.05.004_bib71","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00005392-200102000-00011","article-title":"The ablative effect of quarter dose bacillus Calmette\u2013Gu\u00e9rin on a papillary marker lesion of the bladder","volume":"165","author":"Mack","year":"2001","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib72","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/S0022-5347(05)65642-X","article-title":"Mycobacterial cell wall extract for\u00a0treatment of carcinoma in situ of the bladder","volume":"166","author":"Morales","year":"2001","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib73","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0022-5347(17)46976-X","article-title":"Intravesical bacillus Calmette\u2013Gu\u00e9rin-therapy for superficial bladder cancer: Effect of bacillus Calmette\u2013Gu\u00e9rin viability on treatment results","volume":"134","author":"Kelley","year":"1985","journal-title":"J Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib74","first-page":"21","article-title":"Megadose vitamins in bladder cancer: a double-blind clinical trial","volume":"151","author":"Lamm","year":"1994","journal-title":"J\u00a0Urol."},{"key":"10.1016\/j.biopha.2007.05.004_bib75","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","article-title":"The effect of ofloxacin on bacillus Calmette\u2013Gu\u00e9rin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study","volume":"176","author":"Colombel","year":"2006","journal-title":"J Urol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332207001060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332207001060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:38:47Z","timestamp":1760092727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332207001060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":75,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S0753332207001060"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2007.05.004","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: A success story with room for improvement","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2007.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}